Table 4.
Ongoing clinical trials in thyroid carcinoma.
| Treatment | Study design | Inclusion criteria | Primary endpoint | ClinicalTrials.gov identifier |
|---|---|---|---|---|
| Vemurafenib | Phase II
Nonrandomized |
PTC + BRAFV600E | Best overall response rate | NCT01286753 |
| Dabrafenib ± trametinib | Phase II
randomized |
TC + BRAFV600E | ORR | NCT01723202 |
| Vandetanib | Phase III | DTC | PFS | NCT01876784 |
| randomized | ||||
| Vandetanib 300 versus 150 mg/day | Phase IV
randomized |
MTC | ORR | NCT01496313 |
| Vandetanib + bortezomib | Phase I/II
nonrandomized |
Solid tumors (MTC) | ORR + biomarker response | NCT00923247 |
| Cabozantinib | Phase II | DTC | Efficacy + safety | NCT02041260 |
| nonrandomized | ||||
| Decitabine | Phase II
nonrandomized |
PTC + FTC | Restoration radioiodine uptake | NCT00085293 |
| Sunitinib | Phase II | PTC + FTC + MTC | ORR | NCT00381641 |
| nonrandomized | ||||
| Sorafenib + everolimus | Phase II
nonrandomized |
TC | ORR | NCT01141309 |
DTC, differentiated thyroid carcinoma; FTC, follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; ORR, objective response rate; PFS, progression-free survival; TC, thyroid carcinoma.